Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Paratek Pharmaceuticals, Inc. (PRTK)

2.29   0.03 (1.33%) 11-28 09:40
Open: 2.21 Pre. Close: 2.26
High: 2.29 Low: 2.23
Volume: 56,090 Market Cap: 127(M)

Technical analysis

as of: 2022-11-28 9:21:09 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 3.46     One year: 4.26
Support: Support1: 1.87    Support2: 1.55
Resistance: Resistance1: 2.97    Resistance2: 3.65
Pivot: 2.14
Moving Average: MA(5): 2.08     MA(20): 2.47
MA(100): 2.63     MA(250): 2.93
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 22.2     %D(3): 14.2
RSI: RSI(14): 42.9
52-week: High: 4.94  Low: 1.6
Average Vol(K): 3-Month: 395 (K)  10-Days: 364 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PRTK ] has closed below upper band by 33.4%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.28 - 2.29 2.29 - 2.3
Low: 2.18 - 2.19 2.19 - 2.2
Close: 2.24 - 2.26 2.26 - 2.27

Company Description

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Headline News

Mon, 21 Nov 2022
Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference -

Mon, 07 Nov 2022
Paratek Pharmaceuticals Third Quarter 2022 Earnings: Misses Expectations - Simply Wall St

Thu, 03 Nov 2022
Paratek: Q3 Earnings Snapshot - CTPost

Mon, 31 Oct 2022
Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract - GlobeNewswire

Sat, 01 Oct 2022
Paratek Pharmaceuticals (NASDAQ:PRTK) adds US$15m to market cap in the past 7 days, though investors from five years ago are still down 90% - Simply Wall St

Fri, 16 Sep 2022
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Is Expected To Breakeven In The Near Future - Yahoo Finance

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 56 (M)
Shares Float 43 (M)
% Held by Insiders 16.6 (%)
% Held by Institutions 46.4 (%)
Shares Short 3,250 (K)
Shares Short P.Month 4,520 (K)

Stock Financials

EPS -1.18
EPS Est Next Qtl -0.78
EPS Est This Year 0
EPS Est Next Year -3.15
Book Value (p.s.) -3
Profit Margin (%) -76.1
Operating Margin (%) -60.7
Return on Assets (ttm) -26
Return on Equity (ttm) 0
Qtrly Rev. Growth 23.6
Gross Profit (p.s.) 1.4
Sales Per Share 2.09
EBITDA (p.s.) -1.27
Qtrly Earnings Growth 0
Operating Cash Flow -66 (M)
Levered Free Cash Flow -52 (M)

Stock Valuations

PE Ratio -1.92
PEG Ratio 0
Price to Book value -0.76
Price to Sales 1.07
Price to Cash Flow -1.91

Stock Dividends

Dividend 8.01
Forward Dividend 0
Dividend Yield 354.4%
Dividend Pay Date 2014-10-28
Ex-Dividend Date 2014-10-30
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.